Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
about
Molecular testing in lung cancer in the era of precision medicineLandscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination TreatmentCombinational Therapy Enhances the Effects of Anti-IGF-1R mAb Figitumumab to Target Small Cell Lung CancerAntitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(Δ716) mice involves stromal COX-2.Immunoglobulin-like transcript 4 promotes tumor progression and metastasis and up-regulates VEGF-C expression via ERK signaling pathway in non-small cell lung cancer.Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models.Genetic and biochemical alterations in non-small cell lung cancer.Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanomaPancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner.Molecular-targeted agents combination therapy for cancer: developments and potentials.Selumetinib for the treatment of non-small cell lung cancer.Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations.Selumetinib in the treatment of non-small-cell lung cancer.p90/CIP2A mediates breast cancer cell proliferation and apoptosis.Aquaporin 3 knockdown suppresses tumour growth and angiogenesis in experimental non-small cell lung cancer.Utility and applications of orthotopic models of human non-small cell lung cancer (NSCLC) for the evaluation of novel and emerging cancer therapeutics.Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer.NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition.Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies.Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.In vivo antitumor effect of endostatin-loaded chitosan nanoparticles combined with paclitaxel on Lewis lung carcinoma.The prognostic significance of growth factors and growth factor receptors in gastric adenocarcinoma.Repurposing sertraline sensitizes non-small cell lung cancer cells to erlotinib by inducing autophagy.Contrast-enhanced computed tomography combined with Chitosan-Fe3O4 nanoparticles targeting fibroblast growth factor receptor and vascular endothelial growth factor receptor in the screening of early esophageal cancer.
P2860
Q26824599-EFC88F07-E7C7-45A8-B132-482ECC1FADE8Q27313653-4E64C9FB-8C8E-494C-B706-5A41CA90EC1EQ28547364-666AD068-F622-465D-8947-70E0BCC22A79Q35754265-9AB879CC-F8D1-4D19-9E17-9AD397306B9EQ35955383-4C536AC9-2E64-496C-9451-046CD18954A6Q36047366-206531AA-87A8-486E-9F90-8E87A5538C01Q36184584-35BFE3FB-43B2-4254-8C2D-3DE8E4BAD0EBQ36291134-04ED01C5-F568-4FBE-A5F2-57AE4B92FF98Q37203714-ABEB8F11-CC70-42AA-AB8B-A99926E427BCQ38104670-992D65AA-24B4-4722-9FE9-1B466A5C5A5FQ38663069-35E95C05-460B-4440-8FF1-759C89EAEBD0Q38740315-BA01FF7F-0833-49B0-BF77-CADCE5A48E86Q38836927-95A34D1C-3D91-4246-A219-36E1E82BE128Q38969283-C52C35B0-E4D9-428F-A8EB-AFA7A9668C9BQ38997663-08554582-DBD2-489D-A02B-69A396A729E3Q39025641-7746DA2E-FDCD-48A7-85AF-395C2C0D419FQ39186300-26C79CB8-A965-4E7D-9D40-76C6C84FC4A2Q39466460-B9C4C0B0-8319-4D88-B99E-9C8152D67DADQ41815541-560E697A-F6B0-4CE2-9333-32215235B779Q43515124-12D3A5E2-75A8-4D46-BF23-09AB7C073F59Q45937494-AE349394-C4E7-4D42-BBEC-F152AECA1ADFQ47769437-35F77CC7-E1E1-49D0-A003-307B49976C8CQ53358684-CF4A87ED-5AFB-41AD-B5EE-3FF56A40221EQ54976863-8EA073EF-9BB9-4FF9-A7EA-518D300A93E1Q55081687-D4571EFE-D44F-4929-8C7E-839D5CA6A379
P2860
Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Combined MEK and VEGFR inhibit ...... nesis, growth, and metastasis.
@ast
Combined MEK and VEGFR inhibit ...... nesis, growth, and metastasis.
@en
type
label
Combined MEK and VEGFR inhibit ...... nesis, growth, and metastasis.
@ast
Combined MEK and VEGFR inhibit ...... nesis, growth, and metastasis.
@en
prefLabel
Combined MEK and VEGFR inhibit ...... nesis, growth, and metastasis.
@ast
Combined MEK and VEGFR inhibit ...... nesis, growth, and metastasis.
@en
P2093
P2860
P50
P1476
Combined MEK and VEGFR inhibit ...... nesis, growth, and metastasis.
@en
P2093
Anderson Ryan
Anna Biernacka
B Nebiyou Bekele
Baruch Erez
Juliane M Jürgensmeier
Jörg J Jacoby
Keiko Hosho
Maria V Korshunova
Michael S O'Reilly
Osamu Takahashi
P2860
P304
P356
10.1158/1078-0432.CCR-11-2324
P407
P577
2012-01-24T00:00:00Z